Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3402113 | Enfermedades Infecciosas y Microbiología Clínica | 2010 | 6 Pages |
Abstract
FDCA are a significant advance in antiretroviral treatment simplification, contributing to increase compliance of complex chronic therapies, thus increasing the patient's quality of life. They reduce the risk of treatment errors and can also reduce the possibility of unprescribed monotherapy with selective non-compliance. Hence, they contribute to reduce the risk of selection of HIV-1 clones with antiretroviral resistance, a situation that not only compromises future treatment options of the infected individual, but can also be transmitted and are a situation of Public Health concern. Excluding those cases that require a particular dose adjustment, FDCA are a preferred treatment option and their use must be strongly recommended in all scenarios where the components included in the combination are preferred drugs.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
Josep M. Llibre, Antonio Antela, José Ramón Arribas, Pere Domingo, Josep M. Gatell, José López-Aldeguer, Fernando Lozano, Celia Miralles, José Moltó, Santiago Moreno, Enrique Ortega, Melcior Riera, Antonio Rivero, Concepción Villalonga,